Business news from Ukraine

DECLINE IN CORONAVIRUS SLOWING DOWN IN UKRAINE

The decline in the incidence of the coronavirus (COVID-19) disease in Ukraine is slowing down, but there is currently no high risk of an increase, experts from Kyiv School of Economics (KSE) have said.
“The situation with the incidence in Ukraine continues to decline in terms of the number of detected cases. At the same time, the decline rate is slowing down,” Head of KSE Center for Health Economics Yuriy Hanychenko said during an online presentation of an analysis of the situation with the spread of COVID-19.
At the same time, he said that an outbreak of the disease in the country is possible in July-August – everything will depend on how the situation with the spread of the British, South African and Indian strains of the virus will develop in Ukraine.
“However, in the next week or two, we do not expect a significant increase in the incidence,” Hanychenko said.
According to him, the average daily number of deaths in Ukraine continues to decline and amounts to 31 deaths per day.
“The number of hospitalizations has stopped declining and reached a plateau. This may be the result of a long weekend. At the same time, discharges continue to exceed hospitalizations by more than 1.5 times. The number of patients with COVID-19 is reduced by 20% per week. This week, there was an increase in the level of hospitalizations in Luhansk region by over 60%, but this growth was technical,” Hanychenko said.
At the same time, he noted that three regions need to increase the number of tests.
“In Kyiv, Luhansk and Khmelnytsky regions, the level of testing is falling. It is very dangerous due to the fact that the Delta strain was detected in Ukraine last week. In Kyiv and Luhansk regions, along with the reduction in testing, the detection rate is growing,” Hanychenko said.
KSE said that Ukraine needs to triple the pace of vaccination in order to reach the European level.
“The pace of vaccination in Ukraine is increasing – by a third over the past week. Thanks to this, the lag behind the average European pace of vaccination has decreased, but it still remains high [by three times]. Ukraine needs to triple the pace, there is a vaccine for this,” Hanychenko said.
He said that currently in Ukraine about 62,000 people are vaccinated on average per day. To vaccinate 70% of the population of Ukraine, it is necessary to vaccinate more than 225,000 people daily.

, ,

FARMAK TO ALLOCATE $ 500,000 FOR DEVELOPMENT OF KSE

Farmak pharmaceutical company, within the framework of a strategic partnership with the Kyiv School of Economics (KSE), will allocate $ 500,000 for the development of KSE.
According to a press release from the pharmaceutical company, in particular, the funds will be used to equip a new campus, as well as to strengthen existing and launch new educational areas, including training bachelors.
“By supporting such projects, we are contributing to the achievement of the Global Sustainable Development Goals, one of the tasks of which is to improve the quality of higher education and ensure its close connection with science,” Executive Director of Farmak Volodymyr Kostiuk said.
The press release notes that Farmak supports not only KSE, but also other educational initiatives, including the Minor Academy of Sciences, publishes books about Ukrainian scientists. The company’s own scientific potential (150 scientists, 42 candidates of sciences, five doctors of sciences and an innovative R&D complex) allows providing a high level of academic expertise.
“The decision of Farmak company testifies that Ukrainian business is entering a new level of corporate social responsibility, and this should become an example for others. Thanks to the support of companies such as Farmak, we are preparing the ground for a strong and innovative Ukrainian economy,” President of KSE Tymofiy Mylovanov said.
Farmak is the leader of the Ukrainian pharmaceutical market, produces medicines in all 14 therapeutic groups. Annually it introduces to the market about 20 new complex component modern drugs. Currently, there are about 100 drugs in development. It exports products to more than 25 countries around the world.

, ,

FARMAK TO GRANT $500,000 FOR DEVELOPMENT OF KYIV SCHOOL OF ECONOMICS

Farmak pharmaceutical company, within the framework of a strategic partnership with the Kyiv School of Economics (KSE), will allocate $ 500,000 for the development of KSE.
According to a press release from the pharmaceutical company, in particular, the funds will be used to equip a new campus, as well as to strengthen existing and launch new educational areas, including training bachelors.
“By supporting such projects, we are contributing to the achievement of the Global Sustainable Development Goals, one of the tasks of which is to improve the quality of higher education and ensure its close connection with science,” Executive Director of Farmak Volodymyr Kostiuk said.
The press release notes that Farmak supports not only KSE, but also other educational initiatives, including the Minor Academy of Sciences, publishes books about Ukrainian scientists. The company’s own scientific potential (150 scientists, 42 candidates of sciences, five doctors of sciences and an innovative R&D complex) allows providing a high level of academic expertise.
“The decision of Farmak company testifies that Ukrainian business is entering a new level of corporate social responsibility, and this should become an example for others. Thanks to the support of companies such as Farmak, we are preparing the ground for a strong and innovative Ukrainian economy,” President of KSE Tymofiy Mylovanov said.
Farmak is the leader of the Ukrainian pharmaceutical market, produces medicines in all 14 therapeutic groups. Annually it introduces to the market about 20 new complex component modern drugs. Currently, there are about 100 drugs in development. It exports products to more than 25 countries around the world.

, ,

ICU WILL ALLOCATE 1 MLN $ FOR DEVELOPMENT OF KYIV SCHOOL OF ECONOMICS

ICU Group will allocate $1 million for the development of Kyiv School of Economics (KSE) as part of the continuation of the program to support education in Ukraine, ICU said in a release.
“In 2016, we were one of the first in Ukrainian business who believed in the mission of KSE and the real desire of the management to realize it. The school is intended to become an intellectual basis for a strong and innovative economy of Ukraine, and it is important for us to direct funds to create such a basis. We have been doing this for five years, and we see a clear result of the efforts of the school – the number of students has grown 10 times, and the list of curricula covers almost all trends in the development of modern economic thought,” the founder of ICU and co-chairman of the board of directors of KSE, Makar Paseniuk, said.
President of Kyiv School of Economics Tymofiy Mylovanov noted the systematic cooperation between the KSE and ICU.
“ICU is one of the first strategic partners of Kyiv School of Economics. KSE and ICU are primarily partners who together generated the most daring ideas and implemented them together: setting a new quality bar for themselves and for others. Ukrainian Financial Forum 2018 and 2019, Ukraine Economy Week are our common and favorite projects aimed at improving the quality of economic and business discussions,” he said.
ICU is one of the founders and sponsors of the Center for Journalism at KSE, where Ukrainian media journalists receive necessary knowledge in the field of economics and finance. Now KSE is opening two modern English-language bachelor’s programs: “Economics and Big-Data” and “IT and Business Analysis.” This became possible, among other things, thanks to the partnership and financial support of ICU.
“I am sure that such a significant investment in the development of education in Ukraine will become a bright precedent for domestic businesses – the flagships of the Ukrainian economy,” he added.
ICU Group is an independent financial group, founded in 2006 by specialists from ING, providing brokerage services, asset and private equity management services, as well as venture capital investments. The group specializes in the markets of Central and Eastern Europe.

, , ,